Skip to content
‹ Back to IndustriesHealthcare

Recap: WBCT Society Scientific Meeting

The Weight-Bearing CT Society held its latest Scientific Meeting in Las Vegas this past March during the AAOS 2019 conference. Co-sponsored by CurveBeam, the Scientific Meeting featured an education-packed agenda to discuss the revolutionary transformation weight-bearing technology is having on the imaging industry. First to present was Dr. Alexej Barg, MD, a University of Utah…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The Weight-Bearing CT Society held its latest Scientific Meeting in Las Vegas this past March during the AAOS 2019 conference. Co-sponsored by CurveBeam, the Scientific Meeting featured an education-packed agenda to discuss the revolutionary transformation weight-bearing technology is having on the imaging industry.

First to present was Dr. Alexej Barg, MD, a University of Utah orthopedic surgeon who also served as the moderator for this event. In his presentation discussing imaging of patients with syndesmosis instability, Dr. Barg explained that conventional non-weight-bearing radiograph imaging cannot predict syndesmotic injuries reliably. And while MRI’s demonstrate sensitivity and specificity of nearly 100%, correlating patient complaints with MRI findings can be difficult. Further, although CT technology surpasses conventional imaging methods when 3D MRI or CT imaging is transferred to 2D, there is a substantial loss of information. However, the torque applied in the natural standing position offered higher contrast and spatial resolution of alignment and degeneration, providing a significant advantage in the accuracy of diagnosing syndesmotic injuries.

Dr. Pablo Wagner, MD, of Clinica Alemana in Chile then took the stage for a presentation titled “WBCT for Assessment of Metatarsal Rotation”. Crediting his brother, Emilio Wagner, MD, for his work with hallux valgus patients, Dr. Wagner explained that metatarsal condyles are visible laterally if pronated, of which 87 percent of hallux valgus cases are. If not corrected, metatarsal pronation will result in worse clinical outcomes and higher deformity relapse rates due to the soft tissue balance lateral to the medical ray axis. However, when compared to challenging, unreliable weight-bearing axial sesamoid views and more useful AP foot weight-bearing views on plan X-Ray, weight-bearing CT scans are the gold standard in quantifying metatarsal rotations.

Following Dr. Wagner, Dr. Cesar de Cesar Netto, MD, Ph.D., discussed “WBCT in Patients with AAFD”. While some symptoms or pain are experienced in patients with Adult-Acquired Flatfoot Deformity, it can be difficult knowing when to be more aggressive in treatment to prevent foot collapse. In a study of 55 male and female patients with stage II AAFD, multiple weight bearing CBCT and MRI variables related to the severity of the deformity were evaluated. Weight-bearing CBCT was found to provide more reliability in predicting patients at high risk for foot collapse.

Dr. Arne Burssens, MD, of the Univesity Hospital of Ghent then deliberated on the “Hidden Aspects of a Medializing Calcaneus Osteotomy Revealed by a WBCT”. Difficult to assess via 2D plain radiographic technology, there is a significant difference when assessing MCO in AAFD using weight-bearing imaging versus non-weight-bearing, offering substantial detail to improve understanding with a higher rate of reliability.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

  • 01Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.
  • 02In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.
  • 03Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Nov 22, 2026

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512